Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Mouse |
Target | CD37 |
Clinical data | |
Other names | Tetulomab, HH1 |
ATC code |
|
Identifiers | |
CAS Number |
|
ChemSpider |
|
UNII | |
KEGG |
Lilotomab (formerly tetulomab, HH1) [1] is a murine monoclonal antibody against CD37, [2] a glycoprotein which is expressed on the surface of mature human B cells. [3] It was generated at the Norwegian Radium Hospital. [3]
As of 2016 it was under development by the Norwegian company Nordic Nanovector ASA as a radioimmunotherapeutic in which lilotomab is conjugated to the beta radiation-emitting isotope lutetium-177 by means of a linker called satetraxetan, a derivative of DOTA. [2] This compound is called 177Lu-HH1 or lutetium (177Lu) lilotomab satetraxetan (trade name Betalutin). [1] As of 2016, a phase 1/2 clinical trial in people with non-Hodgkin lymphoma was underway. [4]
Treatment of lymphoma with targeted internal radiation therapy (Betalutin)
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Mouse |
Target | CD37 |
Clinical data | |
Other names | Tetulomab, HH1 |
ATC code |
|
Identifiers | |
CAS Number |
|
ChemSpider |
|
UNII | |
KEGG |
Lilotomab (formerly tetulomab, HH1) [1] is a murine monoclonal antibody against CD37, [2] a glycoprotein which is expressed on the surface of mature human B cells. [3] It was generated at the Norwegian Radium Hospital. [3]
As of 2016 it was under development by the Norwegian company Nordic Nanovector ASA as a radioimmunotherapeutic in which lilotomab is conjugated to the beta radiation-emitting isotope lutetium-177 by means of a linker called satetraxetan, a derivative of DOTA. [2] This compound is called 177Lu-HH1 or lutetium (177Lu) lilotomab satetraxetan (trade name Betalutin). [1] As of 2016, a phase 1/2 clinical trial in people with non-Hodgkin lymphoma was underway. [4]
Treatment of lymphoma with targeted internal radiation therapy (Betalutin)